Comparer des méthodes

	EORTC QLQ-LC13 : Qualité de vie dans le cancer du poumon	EORTC QLQ-CX24 : Qualité de vie dans le cancer du col de l'utérus
Domaine	Oncologie	Oncologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	1994	2006
Auteur d'origine	Bergman, B., et al. (EORTC Quality of Life Group)	Greimel, E. R., et al. (EORTC Quality of Life Group)
Type	Self-report questionnaire	Self-report questionnaire
Source fondatrice	Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642.	Greimel, E. R., Kuljanic Vlasic, K., Zwahlen, D., Rand, K., Heitz, U., Havsteen, H., et al. (2006). The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Acta Oncol, 45(3), 344–351.
Alias	QLQ-LC13	QLQ-CX24
Apparentées	5	5
Résumé	The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials.	The EORTC QLQ-CX24 is a 24-item cervical-cancer-specific module designed to complement the EORTC QLQ-C30 core questionnaire. Developed by Greimel et al. in 2006, it measures sexual/vaginal function, body image, lymphedema, neuropathy, and gastrointestinal symptoms specific to cervical cancer and its treatments. It is the standard cervical cancer-specific QoL instrument in international oncology research.